ANEUVO, a medical technology company advancing non-invasive neuromodulation for people living with spinal cord injury, announced the closing of a Series C funding round of $22M led by Catcher Technology Co., Ltd., with participation from additional new investors. The financing provides additional capital to support the company’s next phase of growth.
Related: Cognito Therapeutics raises $105M for Alzheimer’s therapeutic advancement
The Series C financing marks an important step in ANEUVO’s continued development, providing capital to strengthen its manufacturing capabilities, quality systems, and regulatory initiatives. The investment supports the company’s expansion in approved markets while advancing its long-term commercial and operational infrastructure.
Proceeds from the Series C funding will be used to:
- Execute commercial launch in approved markets and sales expansion
- Scale manufacturing and quality systems to meet global demand
- Advance U.S regulatory activities for ExaStim
- Continue clinical and real-world evidence generation to drive market adoption
The ExaStim Stimulation System delivers personalized spinal cord stimulation, non-invasively, designed to support functional neurorehabilitation for patients with paralysis due to spinal cord injury. ExaStim is a portable neurostimulation device that sends pulses of electricity to a 16-channel multi-electrode array to stimulate nerves along the spinal cord and dorsal roots. The system is controlled via proprietary programming software on a mobile digital device. The ExaStim Stimulation System is CE marked for use in the European Union and is an investigational device, limited by Federal (US) law for investigational use in the United States.
“This financing strengthens the operational and regulatory foundation required to responsibly scale ExaStim,” said Yi-Kai Lo, CEO and Co-Founder of ANEUVO. “We are focused on disciplined execution — building manufacturing readiness, advancing regulatory initiatives, and expanding access in approved markets in a measured and sustainable manner.”
“We are pleased to support ANEUVO at this important stage of its development,” said Catcher Technology Co., Ltd. “The company has demonstrated meaningful progress in advancing its non-invasive neuromodulation platform and has built a strong technical and operational foundation. We believe its disciplined approach to regulatory and commercial execution positions it well to scale operations and expand commercial activities in approved markets. We look forward to supporting the leadership team as they advance their regulatory and manufacturing roadmap.”
